Go Pro

Alcon (ALC) Stock Forecast & Price Target

Alcon logo
$71.81 -0.43 (-0.60%)
As of 11:31 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alcon - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
6
Buy
11

Based on 18 Wall Street analysts who have issued ratings for Alcon in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 1 has given a sell rating, 6 have given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for ALC.

Consensus Price Target

$84.96
18.32% Upside
According to the 18 analysts' twelve-month price targets for Alcon, the average price target is $84.96. The highest price target for ALC is $101.09, while the lowest price target for ALC is $70.00. The average price target represents a forecasted upside of 18.32% from the current price of $71.81.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ALC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alcon and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALC Analyst Ratings Over Time

TypeCurrent Forecast
9/3/25 to 9/3/26
1 Month Ago
8/4/25 to 8/4/26
3 Months Ago
6/5/25 to 6/5/26
1 Year Ago
9/3/24 to 9/3/25
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
10 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$84.96$84.76$85.12$96.06
Forecasted Upside18.32% Upside19.31% Upside27.42% Upside22.15% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ALC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alcon Stock vs. The Competition

TypeAlconHealthcare CompaniesBroader Market
Consensus Rating Score
2.61
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside17.68% Upside815.26% Upside14.07% Upside
News Sentiment Rating
Neutral News

See Recent ALC News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/31/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 Reiterated RatingHold (C-)
8/17/2026 Reiterated RatingBuy
8/13/2026
BNP Paribas Exane logo
BNP Paribas Exane
5 of 5 stars
 DowngradeOutperformNeutral$79.00+7.38%
8/12/2026Boost TargetNeutral$77.53 ➝ $78.40+8.56%
8/12/2026Boost TargetOutperform$80.00 ➝ $85.00+12.96%
8/11/2026Boost TargetBuy$95.00 ➝ $98.00+30.57%
8/11/2026Reiterated RatingBuy$82.00+8.53%
7/2/2026 Set Target$85.00+23.57%
5/8/2026Lower TargetEqual Weight$90.00 ➝ $78.00+22.11%
5/7/2026Lower TargetOverweight$97.00 ➝ $86.00+33.31%
5/7/2026Lower TargetOutperform$98.00 ➝ $90.00+37.08%
5/6/2026 Set Target$70.00+6.62%
1/30/2026 Initiated CoverageMarket Perform
12/11/2025Reiterated RatingBuyUnderperform$100.00 ➝ $75.00-6.48%
12/10/2025 Initiated CoverageOutperform
11/28/2025 Reiterated RatingBuy
11/14/2025Reiterated RatingOutperform$101.09+28.47%
10/21/2025Lower TargetOverweight$98.00 ➝ $91.00+20.59%
10/13/2025 Set Target$91.00+26.40%
8/26/2025 Reiterated RatingOutperform
8/21/2025Lower TargetEqual Weight$84.00 ➝ $80.00+1.40%
5/22/2025UpgradeHoldStrong-Buy
3/25/2025 DowngradeHold
1/10/2025UpgradeNeutralBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:31 AM ET.


Should I Buy Alcon Stock? ALC Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 1, 2026. Please send any questions or comments about these Alcon pros and cons to contact@marketbeat.com.

Alcon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Alcon Inc.:

  • Alcon Inc. recently agreed to lower prescription drug prices for Americans as part of a White House initiative, a move that is expected to bring a $19.6 billion infusion into US plants and potentially improve the company's regulatory standing and market access in the United States.
  • Following strong Q2 2026 results where sales rose 8 percent, Alcon Inc. raised its 2026 earnings growth outlook to target 12 to 15 percent core EPS growth, signaling confidence in its ability to drive profitability despite macroeconomic headwinds.
  • The company plans to reinvest a $60 million tariff refund into its operations, which will help offset previous cost pressures and support margin expansion as it continues to execute its strategic initiatives.
  • Alcon Inc. is currently trading at $71.82, which is below its 52-week high of $87.64, offering a potential entry point for investors who believe the company's recent guidance hikes and product certifications, such as the Clareon Monofocal IOL, will drive future value.
  • Strategic collaborations, such as the partnership with RxSight to co-develop post-operatively adjustable pseudophakic intraocular lenses, position Alcon Inc. to innovate in the cataract and refractive surgery markets, potentially reshaping the future of these procedures.

Alcon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Alcon Inc. for these reasons:

  • Alcon Inc. has stepped away from its PowerVision IOL program, a significant strategic pivot that may raise questions about the company's long-term product roadmap and its ability to maintain a competitive edge in advanced cataract surgery technologies.
  • The company is facing slowing cataract demand and rising competition, which has led some analysts, such as SGA, to exit their positions in Alcon Inc., suggesting that the growth trajectory in its core surgical segment may be facing headwinds.
  • Alcon Inc. carries a high P/E ratio of 54.82, which indicates that the stock is priced at a significant premium relative to its earnings, potentially leaving little room for error if future growth does not meet the raised expectations.
  • Short interest in Alcon Inc. has increased significantly over the past few months, with shares shorted rising from 4.8 million in March 2026 to 11.8 million by August 2026, reflecting growing bearish sentiment among traders who may be betting on a price decline.
  • The company's dividend yield is 0.00%, meaning it does not provide income to investors, which may be a drawback for those seeking a steady cash flow from their healthcare equipment and supplies holdings.

ALC Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Alcon is $84.96, with a high forecast of $101.09 and a low forecast of $70.00.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alcon in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALC shares.

According to analysts, Alcon's stock has a predicted upside of 18.32% based on their 12-month stock forecasts.

Over the previous 90 days, Alcon's stock had 1 downgrade by analysts.

Alcon has been rated by research analysts at Argus, BNP Paribas Exane, BTIG Research, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Mizuho, Needham & Company LLC, and Weiss Ratings in the past 90 days.

Analysts like Alcon more than other "healthcare" companies. The consensus rating for Alcon is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how ALC compares to other companies.


MarketBeat monitors more than a dozen sources for Alcon analyst ratings, with the most recent rating issued on 8/31/2026.
From Our Partners